Please login to the form below

chronic low back pain

This page shows the latest chronic low back pain news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: success for Pfizer and Lilly arthritis drug, Darzalex soars, IMI launches Accelerator

The 16-week study in patients with osteoarthritis (OA) pain evaluated subcutaneous administration of tanezumab, one of a new class of nerve growth factor (NGF) inhibitor drugs. ... In addition to OA pain, the biologic is being evaluated for chronic low

Latest news

FDA fast-tracks Pfizer and Lilly's tanezumab

pain. The US FDA gave the status to tanezumab as a treatment for osteoarthritis and chronic low back pain in patients who cannot adequate pain relief or cannot tolerate currently available ... potential. They estimate that there are more than 27 million
FDA halts study of Teva and Regeneron's pain drug fasinumab

The FDA placed a clinical hold on a phase IIb trial of Teva and Regeneron's nerve growth factor (NGF) inhibitor fasinumab in chronic lower back pain on safety concerns. ... We look forward to working with global health authorities to advance this
Pfizer sales down but oncology shows promise

pegged back by the termination of a collaboration with Boehringer Ingelheim on chronic obstructive pulmonary disease (COPD) treatment Spiriva (tiotropium) in some markets. ... The company has also joined forces with Lilly to develop anti-nerve growth
Lilly's Cymbalta approved for new use

osteoarthritis and chronic lower back pain. ... The marketing application for the latest indication was supported by relatively small clinical studies enrolling about 600 patients with chronic low back pain or chronic pain due to osteoarthritis who
FDA advisors back expanded Cymbalta use

broader population after reviewing safety and efficacy data from studies testing the drug for chronic low back pain and for chronic pain due to osteoarthritis of the knee. ... For people living with chronic low back pain and chronic pain due to

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

Deal Watch table for November 2013

prostate cancer. 2, 400. Pfizer / Lilly. Co-development. Shared development of tanezumab (anti-nerve growth factor) for the treatment of osteoarthritis, chronic low back and cancer pain. ... hyperactivity disorder, pain, urology and allergy. 1, 600.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Director – UK Office: Excellent salary and benefits

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Events Executive: DOE

Account Manager – Healthcare advertising: Salary TBC

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Subscribe to our email news alerts

PMHub

Add my company

Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...